Evidence map›Paper›PMID 26944927›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2016

T Cell Priming by Activated Nlrc5-Deficient Dendritic Cells Is Unaffected despite Partially Reduced MHC Class I Levels.

Giorgia Rota, Kristina Ludigs, Stefanie Siegert, Aubry Tardivel, Leonor Morgado, Walter Reith, Aude De Gassart, Greta Guarda

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Frontiers in immunology · 2020
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. NLRC5, a promising new entry in tumor immunology.Journal for immunotherapy of cancer · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giorgia RotaDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland;
Kristina LudigsDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland;
Stefanie SiegertLudwig Center for Cancer Research, University of Lausanne, 1066 Epalinges, Switzerland; and.
Aubry TardivelDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland;
Leonor MorgadoDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland;
Walter ReithDepartment of Pathology and Immunology, University of Geneva Medical School, 1211 Geneva, Switzerland.
Aude De GassartDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland;
Greta GuardaDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland; Greta.Guarda@unil.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NLRC5, a member of the NOD-like receptor (NLR) protein family, has recently been characterized as the master transcriptional regulator of MHCI molecules in lymphocytes, in which it is highly expressed. However, its role in activated dendritic cells (DCs), which are instrumental to initiate T cell responses, remained elusive. We show in this study that, following stimulation of DCs with inflammatory stimuli, not only did NLRC5 level increase, but also its importance in directing MHCI transcription. Despite markedly reduced mRNA and intracellular H2-K levels, we unexpectedly observed nearly normal H2-K surface display in Nlrc5(-/-) DCs. Importantly, this discrepancy between a strong intracellular and a mild surface defect in H2-K levels was observed also in DCs with H2-K transcription defects independent of Nlrc5. Hence, alongside with demonstrating the importance of NLRC5 in MHCI transcription in activated DCs, we uncover a general mechanism counteracting low MHCI surface expression. In agreement with the decreased amount of neosynthesized MHCI, Nlrc5(-/-) DCs exhibited a defective capacity to display endogenous Ags. However, neither T cell priming by endogenous Ags nor cross-priming ability was substantially affected in activated Nlrc5(-/-) DCs. Altogether, these data show that Nlrc5 deficiency, despite significantly affecting MHCI transcription and Ag display, is not sufficient to hinder T cell activation, underlining the robustness of the T cell priming process by activated DCs.

Indexed as

AnimalsAntigen PresentationCell LineCell MembraneCross-PrimingDendritic CellsGene Expression RegulationHistocompatibility Antigens Class IIntracellular Signaling Peptides and ProteinsLymphocyte ActivationMiceMice, KnockoutT-LymphocytesTranscription, GeneticHistocompatibility Antigens Class IIntracellular Signaling Peptides and ProteinsNLRC5 protein, mouse

Identifiers

PMID26944927
PMCPMC4797726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.